Skip to main content

Natural Product Inspired Design of Enediyne Prodrugs via Rearrangement of an Allylic Double Bond

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

Cyclodeca-1,5-diyn-3-ene, the parent core of naturally occurring 10- membered ring enediyne antitumor antibiotics, decomposes at 37°C with a t1 / 2 value of 18 h. A prodrug approach was envisaged by in situ formation of the core structure via rearrangement of an allylic double bond. Three synthetic methods including intramolecular lithium acetylide addition to aldehyde, intramolecular Nozaki-Hiyama- Kishi reaction, and intramolecular Sonogashira cross-coupling have been established for synthesis of the enediyne precursors, (E)-3-acyloxy-4-(arylmethylidene)cyclodeca- 1,5-diynes. The latter are transformed into 10-membered ring enediynes in the presence of a catalytic amount of Ln(fod)3 under mild reaction conditions. Alternatively, the enediyne precursor dissociates in buffer solution into an allylic cation or a quinone methide intermediate, which reacts with a nucleophile (such as H2O) to form the bioactive enediyne. LC-MS data confirmed formation of the 10-membered ring enediyne from the precursor, which exhibits DNA cleavage activity and cytotoxicity against P388 cancer cell line.

Keywords: cytotoxicity; diradical; dna; enediyne; prodrug; rearrangement

Document Type: Review Article

DOI: https://doi.org/10.2174/0929867033456756

Affiliations: Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR, China.

Publication date: 2003-11-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more